For the fifth consecutive year, SGS Health Science has been recognised by the exclusive CRO Leadership Awards. In the 2021 awards, SGS was delighted to win three awards for its industry-leading compatibility, reliability and quality across two groups of respondents (Big Pharma and Overall).
The awards, which were first launched back in 2012 by the highly respected business journals Life Science Leader and Clinical Leader, seek to reward leading clinical research organisations (CROs) operating within the life sciences industry.
According to Johan Pype, managing director of SGS Benelux: “We are thrilled to have achieved wins in three categories, particularly as this recognition is based on genuine customer feedback.
“We always strive to provide the best possible customer experience and this recognition is testament to the dedication of our very talented employees, the depth of our clinical expertise, and our company-wide commitment to consistently delivering high quality to our customers.”
As Ed Miseta, chief editor of Clinical Leader, states: “These award winners have proven themselves to be the top service providers in each category. I congratulate all of them for the work ethic they exhibit in consistently meeting the needs of their drug development clients.”
These awards come after a particularly busy year for the SGS team. Throughout the past 12 months, we have, for example, provided biosafety, quality control and clinical research solutions to Covid-19 vaccine candidates.
SGS has a wealth of expertise in early clinical development studies, providing end-to-end clinical trial solutions. These services encompass full early phase drug development consultancy, clinical project management and monitoring, biometrics, regulatory and medical affairs services.
The SGS team has also been busy developing the company’s brand new clinical pharmacology unit (CPU) on the grounds of the University Hospital of Antwerp, Belgium, which will open later this year.
The new CPU will allow SGS to further develop its significant capabilities and safeguard its position as an expert CRO.